Project Highlights

MoA：

Guanylate cyclase 2C (GCC) is encoded by GUCY2C gene in human body. The receptor has an extracellular ligand binding domain, a transmembrane region, a region similar to the protein kinase sequence and a c-terminal guanylate cyclase domain. GCC signal pathway can inhibit cell proliferation, protect tight connections between cells, inhibit p53 degradation, promote DNA damage repair, reduce cell cycle progression, and promote oxidative phosphorylation.
GCC is highly expressed in colorectal cancer, gastric cancer and esophageal cancer, and only in intestinal and colon tissues in normal tissues, but not in other tissues.

1.Excellent preclinical results:

Compared with Benchmark (PF-07062119), this antibody has better affinity for HEK293T-hGCC cells.
The binding epitope of the antibody to GCC is different from the natural ligand guanosine protein of GCC.
The antibody can be rapidly internalized by 293T-hGCC cells.
GCC-CD3 BsAb can effectively activate Jurkat cells; Activates T-cell-mediated cytotoxic effects.

Research progress:

Ongoing Preclinical research:

Anti-GCC humanized antibody has high affinity.

It is different from the natural GCC ligand binding epitope.

GCC-CD3 BsAb can activate T cells and T-cell-mediated cytotoxic effects.